Anti-HER2 targeted ADCs, trastuzumab-deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1), were first introduced in the treatment of HER2-overexpressing breast cancers but are a relatively new addition in lung cancer care. This evidence concerns the gene ERBB2 and lung cancer.